908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.12 · Revenue $18.57M · 2 analysts
Est. EPS $-0.07 · Revenue $21.15M · 2 analysts
Est. EPS $-0.77 · Revenue $69.21M · 2 analysts
Est. EPS $-0.12 · Revenue $17.20M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $56.2M | -5.8% | +20.1% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-36.6M | +49.3% | +0.5% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +47.7% | -5.0% | +8.9% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -43.0% | +66.6% | -64.0% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -65.2% | +46.2% | +17.2% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-24.6M | +20.1% | +188.2% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -43.9% | +15.2% | +139.9% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 11.6% | +101.6% | +1.9% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 4.24x | +3.6% | -25.4% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $190.1M | +19.2% | +5.8% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.94 vs -0.62 | -51.7% | -0.32 vs -0.14 | -125.4% |
| Revenue Surprise | $56.2M vs $54.6M | +2.8% | $16.1M vs $15.4M | +4.6% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 25, 2026 | Griffith Joseph H. IV | officer: Chief Financial Officer | Common Stock | D | 11,459 | $10.95 |
| Aug 21, 2026 | AWM Investment Company, Inc. | 10 percent owner | Common Stock | D | 41,578 | $10.61 |
| Aug 20, 2026 | AWM Investment Company, Inc. | 10 percent owner | Common Stock | D | 8,422 | $10.52 |
| Aug 17, 2026 | Knopp Kevin J. | director, officer: President and CEO | Common Stock | D | 20,000 | $10.35 |
| Aug 13, 2026 | Knopp Kevin J. | director, officer: President and CEO | Common Stock | D | 7,622 | $10.06 |
Operator : Hello, everyone. Thank you for joining us, and welcome to the 908 Devices Second Quarter 2026 Earnings Call. [Operator Instructions] I will now hand the conference over to Barbara Russo in Investor Relations. Barbara, please go ahead. Barbara Russo : Thank you, and good morning. On this call, we will be discussing our financial results for the second quarter ending June 30, 2026, which were released earlier this morning. Joining me from 908 Devices is Kevin Knopp, Chief Executive Officer and Co-Founder; and Joe Griffith, Chief Financial Officer. During today's call, we will make forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. For a discussion of these risks and uncertainties, please review the forward-looking statement disclosure in the earnings news release as well as in our most recent annual report on Form 10-K and other SEC filings. These forward-looking statements reflect management's beliefs and assumptions as of the date of this live broadcast, August 11, 2026. Except as required by law, we disclaim any obligation to update forward-looking statements to reflect future events or circumstances. Our commentary today will also include non-GAAP financial measures, which should be considered as a supplement to and not a substitute for GAAP financial measures. The non-GAAP reconciliations can be found in today's earnings press release, which is available in the Investor Relations section of our website. With that, I now turn the call over to Kevin. Kevin Knopp : Thanks, Barbara. Good morning, and thank you for joining our second quarter 2026 earnings call. I'm pleased to report that we delivered strong results this quarter, demonstrating the power of our strategy and dedication of our team. In the second quarter, we generated $16.1 million in revenue, representing 23% growth year-over-year. Our momentum with U.S. state and local customers remain particularly strong with these customers representing more than half of our revenues in the second quarter. We're seeing continued funding support at the state and local level, driven by the urgent need to modernize detection capabilities in response to evolving threats from the ongoing fentanyl crisis to emerging synthetic drugs and chemical hazards. This funding momentum, combined with strong customer demand, gives us confidence in the durability of this growth trajectory. From a profitability standpoint, we are making meaningful progress. The cost structure initiatives we implemented last year are delivering results. Our adjusted EBITDA loss was less than $2 million in the second quarter, which is a 50% improvement year-over-year. These improvements demonstrate our commitment to scale efficiently while investing in growth. As announced on May 6, we acquired NIRLAB, expanding our narcotics detection portfolio. We now …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Kevin J. Knopp | Co-Founder, Chief Executive Officer, President & Director | USD 1,028,500 | — | 1973 | Active |
Joseph H. Griffith | Chief Financial Officer & Treasurer | USD 796,756 | Male | 1975 | Active |
John Kenneweg | Senior Vice President of Sales and Product Marketing | USD 783,621 | Male | 1973 | Active |
Christopher David Brown | Co-Founder, Board Advisor & Director | USD 555,607 | — | 1975 | Active |
Mark S. Levine | Chief Legal, Administrative Officer & Corporate Secretary | USD 335,429 | Male | 1973 | Active |
Kola Otitoju | Chief Business & Strategy Officer | — | Male | 1973 | Active |
Barbara Russo | Vice President of Corporate Marketing and Communications | — | Female | 1964 | Active |
Don Osmer | Vice President of Human Resources | — | Male | 1966 | Active |
Kevin McCallion | Senior Vice President of Products and Production | — | Male | 1966 | Active |
908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago.
908 Devices NASDAQ: MASS is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement following the divestiture of its bioprocessing and biopharma business line, executives said during a Canaccord Genuity discussion.
908 Devices delivered another revenue beat in Q2, as device sales continued to shine. Q2 revenues grew 23% year-over-year to $16.07 million, with product revenue up nearly 35.5% and the installed base expanding 23%. Management raised 2026 revenue guidance to $68–$70 million, implying 21–25% growth, while operating and net losses narrowed.
908 Devices is rated BUY after a 2Q26 earnings beat, strong revenue growth, and a 97% YTD share price gain. MASS benefits from robust demand for chemical detection devices, driven by law enforcement, defense, and volatile geopolitical conditions. Recurring revenue from NIRLab and product upgrades like VipIR underpin stable growth; management raised FY26 revenue guidance to $68–$70M.
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that CEO and Co-founder Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings at the 17th Annual Midwest IDEAS Conference on Wednesday, August 26, 2026. The Company presentation is scheduled to begin at 9:55 a.m. CT / 10:55 a.m. ET. The presentation is.
